BEAMBeam Therapeutics Inc.

$3B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$114M+279.5% YoY

Gross Profit

$108M95.0% margin

Operating Income

-$17M-15.3% margin

Net Income

$244M214.1% margin

EPS (Diluted)

$2.33

QoQ Revenue Growth

+1076.6%

Cash Flow

Operating Cash Flow

-$83M

Free Cash Flow

-$87M

Stock-Based Comp.

-$74M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$243M

Stockholders' Equity

$1.2B

Cash & Equivalents

$295M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$114M	$30M	+279.5%
Gross Profit	$108M	-$71M	+251.9%
Operating Income	-$17M	-$100M	+82.6%
Net Income	$244M	-$90M	+370.4%

BEAM Q4 2025 Earnings — Beam Therapeutics Inc. Revenue & Financial Results | Market Cap Arena